Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 8/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 8/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 8/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | C1S | P09871 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | F7 | P08709 | 5/20 | 0.35 |
| ▸ | F10 | P00742 | 5/20 | 0.35 |
| ▸ | F2 | P00734 | 4/20 | 0.35 |
| ▸ | F12 | P00748 | 1/20 | 0.35 |
| ▸ | F3 | P13726 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 7/20 | 0.35 |
| ▸ | PLAT | P00750 | 6/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | F9 | P00740 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32689453 | 0.84 | BCAT2 (0.63) | BCAT2PRSS1PRSS2PRSS3KMT2A | |
| SCHEMBL1034554 | 0.84 | BCAT2 (0.63) | BCAT2PRSS1PRSS2PRSS3KMT2A | |
| Hydrochloric Acid SCHEMBL27450056 | 0.82 | BCAT2 (0.61) | BCAT2PRSS1PRSS2PRSS3KMT2A | |
| Hydrochloric Acid SCHEMBL31621742 | 0.82 | BCAT2 (0.61) | BCAT2PRSS1PRSS2PRSS3KMT2A | |
| Ammonia Solution, Strong SCHEMBL29131061 | 0.82 | BCAT2 (0.61) | BCAT2PRSS1PRSS2PRSS3KMT2A | |
| SCHEMBL208788 | 0.81 | BCAT2 (0.71) | BCAT2KMT2ARECQLMEN1SMN1; SMN2 | |
| SCHEMBL7395394 | 0.80 | BCAT2 (0.42) | BCAT2PRSS1PRSS2PRSS3KMT2A | |
| SCHEMBL752611 | 0.79 | F2 (0.48) | BCAT2PRSS1PRSS2PRSS3KMT2A | |
| SCHEMBL7367739 | 0.78 | BCAT2 (0.35) | BCAT2KMT2ALMNAMEN1SMN1; SMN2 | |
| SCHEMBL7151686 | 0.78 | BCAT2 (0.55) | BCAT2PRSS1PRSS2PRSS3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1925611-B1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| CN-103214414-B | The diamine derivative of opticity and manufacture method thereof | SANKYO CO. (JP) | 2016-02-17 | — | — | CN | disclosed |
| CN-103214414-A | Optically active diamine derivative and process for producing the same | DAIICHI SANKYO CO LTD | 2013-07-24 | — | — | CN | disclosed |
| CN-101263110-B | Optically active diamine derivative and process for producing the same | DAIICHI SANKYO CO LTD | 2013-04-03 | — | — | CN | disclosed |
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-1864982-A1 | TRIAMINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | BCAT2 2009/4885PRSS1 657/4885PRSS2 843/4885 |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | BCAT2 331/4885PRSS1 616/4885PRSS2 347/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | BCAT2 1261/4885PRSS1 166/4885PRSS2 372/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | BCAT2 915/4885PRSS1 412/4885PRSS2 606/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | BCAT2 915/4885PRSS1 412/4885PRSS2 606/4885 |
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | BCAT2 1189/4885PRSS1 510/4885PRSS2 725/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | BCAT2 915/4885PRSS1 412/4885PRSS2 606/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | BCAT2 447/4885PRSS1 596/4885PRSS2 1219/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | BCAT2 1100/4885PRSS1 520/4885PRSS2 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.